<i>In Silico</i> evaluation of the anti-influenza potential of <i>Streptomyces</i> bioactive compounds

Influenza, a highly contagious respiratory viral disease characterized by its short incubation period and severe symptoms, is treatable with antiviral drugs targeting viremia. Among new antiviral agents, Actinobacteria, particularly from the Streptomyces genus, are notable for their ability to produce potent antiviral compounds. This study evaluates the antiviral potential of Streptomyces sp. KSF 103, isolated from Kuala Sat, Jerantut, Pahang, against the Influenza A virus (IAV). Using molecular docking tools such as AutoDock Vina and PyMOL, the interactions of four compounds – hypoxanthine, vitamin D, purine, and aminocaproic acid – were analyzed against IAV proteins. Vitamin D exhibited the highest binding affinity against H3N2’s M2 (−9.6 kcal/mol) and HA (−9.2 kcal/mol) proteins. Additionally, RMSD dynamics parameters indicated that the best-scoring complexes are predicted to be satisfactorily stable under physiological settings. These findings suggest that Streptomyces sp. KSF 103 could be a promising source for developing new antiviral treatments against influenza.